Has Mitchell Miglis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $51,186 in general payments to Mitchell Miglis, MD across 77 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mitchell Miglis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mitchell Miglis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mitchell Miglis, MD

Clinical Neurophysiology · Stanford, CANPI 1972779411

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $32,622 of the $51,186 with a category attached, or 63.7%. Jazz Pharmaceuticals Inc. accounts for 90.5% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $21,981, more than ten times the $41 reported in 2019. Among clinical neurophysiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,186in general payments, 2019–2025

Across 77 payments — averaging $664.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$46K
Lundbeck LLC$3K
Argenx US, Inc.$696
Pfizer$550
Harmony Biosciences LLC$356
Alnylam Pharmaceuticals Inc.$41

$774,566in research payments, 2019–2025

Across 351 payments — averaging $2206.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Argenx US, Inc.$599K
Regeneron$118K
Biohaven Pharmaceuticals, Inc.$35K
Biohaven Pharmaceutical Holding Company Ltd.$22K

What the payments were for

Consulting fees$32,62264%
Speaking & faculty fees$12,44024%
Travel & lodging$2,1824%
Food & beverage$3,9428%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	57	$46,344
Lundbeck LLC	1	$3,200
Argenx US, Inc.	12	$696
Pfizer	1	$550
Harmony Biosciences LLC	5	$356
Alnylam Pharmaceuticals Inc.	1	$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XYWAV$36,739
SUNOSI$4,560
VYVGART$348
XYREM$300

How this compares

$51,186 in reported general payments places this provider in the 90th percentile of 49 clinical neurophysiology providers in California.

See all clinical neurophysiology providers in California →

Medicare billing

Part B allowed, 2024

$80,530

Medicare patients

395

Services billed

675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XywavSodium,calcium,mag,pot Oxybate	22	$263,877
Sodium Oxybate	12	$223,329
Droxidopa	83	$169,359
Gamunex-CImmune Globul G/Gly/Iga Avg 46	22	$68,123
BelsomraSuvorexant	35	$18,142
NeuproRotigotine	18	$16,169
Midodrine Hcl	80	$7,655
Cromolyn Sodium	20	$5,342
Modafinil	70	$2,845
Pyridostigmine Bromide	45	$2,742
Gabapentin	114	$1,846
Carbidopa-LevodopaCarbidopa/Levodopa	23	$1,475
Atomoxetine Hcl	23	$1,218
Fludrocortisone Acetate	39	$977
Carbamazepine	26	$802

Paid to pharmacies, not to this prescriber.

Other clinical neurophysiology in Stanford

Christopher LockStanford$159K
Srikanth MuppidiStanford$150K
Safwan JaradehStanford$34K
Margaret FerrisStanford$18K
Kathleen PostonStanford$18K
Helen Bronte-StewartStanford$7K
Jaime LopezStanford$1K
Sungho ChoStanford$1K
Felix ChangStanford$974
Laurice YangStanford$924

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →